Armistice Capital’s Novo Nordisk NVO Stock Holding History

Armistice Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-336,000	Closed	-$17.1M	–	408
2025 Q4	$17.1M	Sell	336,000 -400,000	-54%	-$20.5M	0.2%	78
2025 Q3	$40.8M	Buy	+736,000	New	+$43.1M	0.61%	25
2025 Q2	–	Sell	-108,000	Closed	-$7.5M	–	250
2025 Q1	$7.5M	Sell	108,000 -604,000	-85%	-$49.9M	0.11%	100
2024 Q4	$61.2M	Buy	712,000 +147,000	+26%	+$15.9M	0.84%	24
2024 Q3	$67.3M	Buy	565,000 +21,000	+4%	+$2.8M	1.08%	16
2024 Q2	$77.7M	Buy	544,000 +144,000	+36%	+$19.1M	0.98%	11
2024 Q1	$51.4M	Buy	400,000 +4,000	+1%	+$476K	0.68%	19
2023 Q4	$41M	Sell	396,000 -40,000	-9%	-$3.96M	0.56%	32
2023 Q3	$39.6M	Sell	436,000 -104,000	-19%	-$9.16M	0.61%	34
2023 Q2	$43.7M	Sell	540,000 -44,000	-8%	-$3.59M	0.63%	33
2023 Q1	$46.5M	Sell	584,000 -40,000	-6%	-$2.84M	0.67%	32
2022 Q4	$42.2M	Buy	+624,000	New	+$36.6M	0.74%	32

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Armistice Capital's NVO Position: Q1 2026 in Review

Armistice Capital sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 336,000 shares — an estimated $17.1M sold.

Armistice Capital first reported a position in NVO in Q4 2022 and held it in 12 quarters. The position peaked at $77.7M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Armistice Capital reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Armistice Capital sold 336,000 Novo Nordisk shares in Q1 2026, an estimated $17.1M.
Armistice Capital first reported a position in Novo Nordisk in Q4 2022 and held it in 12 quarters.
Armistice Capital's Novo Nordisk position peaked at $77.7M in Q2 2024.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.